Trial Profile
Phase II study evaluating the safety and efficacy of neoadjuvant leuvectin immunotherapy for the treatment of prostate cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuvectin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Vical
- 28 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record..
- 29 Sep 2005 New trial record.